By Adria Calatayud


Alliance Pharma said Thursday that sales for the first four months of 2023 were higher than in the year-earlier period, but warned that adjusted pretax profit for the full year will be marginally lower than expected due foreign-exchange moves and rising interest rates.

The U.K. consumer-healthcare company didn't provide specific figures, but said demand for its Kelo-Cote product in China has continued to recover as expected.

"Whilst the business is on track to meet the board's full year expectations for revenue and adjusted [earnings before interest, taxes, depreciation and amortization], adverse currency movements, particularly the recent strengthening of U.K. sterling against the U.S. dollar, and the rising interest rate environment, mean that full year adjusted profit before tax is expected to be marginally below current expectations," Chair David Cook said.


Write to Adria Calatayud at adria.calatayud@dowjones.com to Adria Calatayud at adria.calatayud@dowjones.com


(END) Dow Jones Newswires

05-25-23 0403ET